pain-neuropathic-spinifex-27.html
Novo Annual Report 2015
28 / 72
d uring 2015,
novo
added five public and 12 private companies to its venture portfolio. in most of the private financing
s, we played a key role as lead or co-lead investors. our new portfolio companies develop therapies for a variety of indications, including migraine, cancer immunotherapy, cns, ophthalmology, glaucoma, immune diseases and anti- infective therapies. except for one, all the new companies are located in the us. anti-infectives nabriva therapeutics (nasdaq:nbrv) develops novel anti-infective agents. the lead product candidate, lefamulin is in phase 3 for the treatment of community-acquired bacterial pneumonia. novo invested in the company
?s ipo. cancer immunotherapy corvus pharmaceuticals develops drugs that reprogramme t cells to restore the immune balance needed for tumour destruction. novo participated in corvus? two financing in 2015. encarta therapeutics plans to develop novel t-cell therapies for cancer. novo was a co-investor in encarta?s financing. merus closed a financing in august that was co-led by novo. the company develops fully human bi-specific antibodies for various oncology indications. nkarta therapeutics is focused on developing natural killer (nk) cell-based therapies for use in the treatment of cancers. novo co-lead the initial financing of the company. unum therapeutics develops antibody-coupled t-cell receptor technology for use in cellular immunotherapies for cancer. novo invested in its recent financing. vasculox develops a portfolio of anti-cd47 therapeutic antibodies for the treatment of cancer and pulmonary hypertension. novo invested in its recent financing. cancer supportive care galera therapeutics closed a financing in october that was led by novo. galera therapeutics is a clinical-stage company with a lead product focused on radiation-induced mucositis. cns colucid pharmaceuticals (nasdaq:clcd) develops innovative therapies for cns disorders and has initiated its first phase 3 pivotal trial to confirm lasmiditan?s safety and efficacy. novo invested in the company?s ipo. e-scape bio closed a financing in august that was co-lead by novo. the company develops a pipeline of apoe4 structure correctors for the treatment of neurodegenerative diseases, including alzheimer?s disease. immune diseases kanyos bio is a spin-out from anokion. the company focuses on autoimmune diseases (e.g. celiac disease and type 1 diabetes) under an option deal with astellas. ra pharmaceuticals closed a financing in july that was co-led by novo. the company focuses on developing peptide-based drugs for treatment of diseases of complement dysregulation. medical devices glaukos (nasdaq:gkos) is focused on the commercialisation of medical devices to treat glaucoma. novo invested in the company?s ipo. invuity (nasdaq:ivty) is pioneering and commercialising the use of advanced photonics to provide surgeons with improved direct visualisation of surgical cavities during minimally invasive surgery. novo invested in the company?s ipo. penumbra (nyse:pen) develops and commercialises innovative medical devices primarily for the neuro and peripheral vascular markets. novo invested in the company?s ipo. procept biorobotics closed a financing in july that was led by novo. the company is developing a new treatment for benign prostate hyperplasia based on robot-controlled water ablation of prostate tissue. unchained labs closed a financing in february that was led by novo. the company develops and markets life science tools for analysing protein stability. introducing the class of 2015 novo a/s 28 novo ventures
2015-million-usd-29.html
